201 related articles for article (PubMed ID: 8393954)
1. Investigation of the mechanism of hypertension in apparent mineralocorticoid excess.
Speiser PW; Riddick LM; Martin K; New MI
Metabolism; 1993 Jul; 42(7):843-5. PubMed ID: 8393954
[TBL] [Abstract][Full Text] [Related]
2. Human hypertension caused by mutations in the 11 beta-hydroxysteroid dehydrogenase gene: a molecular analysis of apparent mineralocorticoid excess.
Whorwood CB; Stewart PM
J Hypertens Suppl; 1996 Dec; 14(5):S19-24. PubMed ID: 9120678
[TBL] [Abstract][Full Text] [Related]
3. Congenital and acquired syndromes of apparent mineralocorticoid excess.
Edwards CR; Walker BR; Benediktsson R; Seckl JR
J Steroid Biochem Mol Biol; 1993 Apr; 45(1-3):1-5. PubMed ID: 8386930
[TBL] [Abstract][Full Text] [Related]
4. Apparent mineralocorticoid excess syndromes.
Shimojo M; Stewart PM
J Endocrinol Invest; 1995; 18(7):518-32. PubMed ID: 9221270
[TBL] [Abstract][Full Text] [Related]
5. Steroid hormones and hypertension: the cortisol-cortisone shuttle.
Stewart PM; Whorwood CB; Walker BR
Steroids; 1993 Dec; 58(12):614-20. PubMed ID: 8116018
[TBL] [Abstract][Full Text] [Related]
6. 11 beta-Hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
White PC; Mune T; Rogerson FM; Kayes KM; Agarwal AK
Pediatr Res; 1997 Jan; 41(1):25-9. PubMed ID: 8979285
[TBL] [Abstract][Full Text] [Related]
7. [A case of apparent mineralocorticoid excess caused by type 2 11 beta- hydroxysteroid dehydrogenase deficiency].
Morineau G; Pascoe L; Marc JM; Caillette A; Krozowski Z; Corvol P; Fiet J
Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1111-5. PubMed ID: 9404418
[TBL] [Abstract][Full Text] [Related]
8. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle.
Stewart PM; Corrie JE; Shackleton CH; Edwards CR
J Clin Invest; 1988 Jul; 82(1):340-9. PubMed ID: 3164727
[TBL] [Abstract][Full Text] [Related]
9. When is cortisol a mineralocorticoid?
Clore J; Schoolwerth A; Watlington CO
Kidney Int; 1992 Dec; 42(6):1297-308. PubMed ID: 1474763
[TBL] [Abstract][Full Text] [Related]
10. Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome?
Palermo M; Delitala G; Sorba G; Cossu M; Satta R; Tedde R; Pala A; Shackleton CH
J Endocrinol Invest; 2000; 23(7):457-62. PubMed ID: 11005270
[TBL] [Abstract][Full Text] [Related]
11. Molecular analysis of 11 beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
White PC; Mune T; Rogerson FM; Kayes KM; Agarwal AK
Steroids; 1997 Jan; 62(1):83-8. PubMed ID: 9029720
[TBL] [Abstract][Full Text] [Related]
12. Apparent mineralocorticoid excess causing hypertension and hypokalemia in children.
New MI; Stoner E; DiMartino-Nardi J
Clin Exp Hypertens A; 1986; 8(4-5):751-72. PubMed ID: 3463439
[TBL] [Abstract][Full Text] [Related]
13. The role of the 11beta-hydroxysteroid dehydrogenase type 2 in human hypertension.
Ferrari P; Lovati E; Frey FJ
J Hypertens; 2000 Mar; 18(3):241-8. PubMed ID: 10726708
[TBL] [Abstract][Full Text] [Related]
14. Defects in the HSD11 gene encoding 11 beta-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency.
Nikkilä H; Tannin GM; New MI; Taylor NF; Kalaitzoglou G; Monder C; White PC
J Clin Endocrinol Metab; 1993 Sep; 77(3):687-91. PubMed ID: 8370690
[TBL] [Abstract][Full Text] [Related]
15. The cortisol-cortisone shuttle and the apparent specificity of glucocorticoid and mineralocorticoid receptors.
Edwards CR; Stewart PM
J Steroid Biochem Mol Biol; 1991 Nov; 39(5B):859-65. PubMed ID: 1659446
[TBL] [Abstract][Full Text] [Related]
16. Apparent mineralocorticoid excess type II.
Mantero F; Tedde R; Opocher G; Dessi Fulgheri P; Arnaldi G; Ulick S
Steroids; 1994 Feb; 59(2):80-3. PubMed ID: 8191552
[TBL] [Abstract][Full Text] [Related]
17. 11beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess.
White PC
Am J Med Sci; 2001 Dec; 322(6):308-15. PubMed ID: 11780688
[TBL] [Abstract][Full Text] [Related]
18. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
Odermatt A; Dick B; Arnold P; Zaehner T; Plueschke V; Deregibus MN; Repetto H; Frey BM; Frey FJ; Ferrari P
J Clin Endocrinol Metab; 2001 Mar; 86(3):1247-52. PubMed ID: 11238516
[TBL] [Abstract][Full Text] [Related]
19. Organ-specific actions of 11 beta-hydroxysteroid dehydrogenase in humans: implications for the pathophysiology of hypertension.
Walker BR
Steroids; 1994 Feb; 59(2):84-9. PubMed ID: 8191553
[TBL] [Abstract][Full Text] [Related]
20. Apparent mineralocorticoid excess.
Funder JW
Endocrinol Metab Clin North Am; 1995 Sep; 24(3):613-21. PubMed ID: 8575412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
